SeaSpine Announces 25,000th NanoMetalene® Implantation

CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the implantation of the 25,000th NanoMetalene^® interbody device.

NanoMetalene is a proprietary surface technology for interbody implants that incorporates a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a high-energy, low-temperature process referred to as atomic fusion deposition. It is designed to provide a bone-friendly titanium surface on endplates and throughout graft apertures, while retaining the benefits associated with traditional PEEK implants, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for postoperative imaging.

“Our proprietary and innovative NanoMetalene surface technology has been, and continues to be, a differentiator in the marketplace,” stated Keith Valentine, President and Chief Executive Officer. “This year alone, NanoMetalene has helped drive US interbody implant revenue at a pace that is six to seven times the market. Our team takes great pride in positively impacting tens of thousands of patients’ lives.”

SeaSpine is committed to advancing the development of differentiated surface materials and novel designs, highlighted by the recent introduction of Reef Topography™ and our partnership with restor3D. The success of NanoMetalene demonstrates that leveraging science and clinical data to deliver implants deliberately designed to facilitate interbody fusion will deliver the best results for patients.

About SeaSpine

SeaSpine () is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Forward-Looking Statements

SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward- looking statements include, but are not limited to, statements relating to: the ability of NanoMetalene to be a differentiator in the marketplace; the Company’s ability to advance the development of differentiated surface materials and novel designs; and the ability to leverage science and data to deliver implants that facilitate fusion and deliver the best results for patients that succeed in the marketplace. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of NanoMetalene and newly launched products to perform as designed and intended and to meet the needs of surgeons and patients; the lack of clinical validation for NanoMetalene surface technology; surgeon’s willingness to continue to use the Company’s NanoMetalene products; the Company’s reliance on a sole provider to apply NanoMetalene surface technology to its products; risks inherent in the development of new medical devices, including as a result of newly initiated collaborations or the use of nascent manufacturing techniques or processes; unexpected delay, including as a result of developing and supporting the launch of new products, including the fact that newly launched products may require substantial additional development activities, which could introduce further delay, or as a result of obtaining regulatory clearances; general economic and business conditions in the markets in which the Company does business, both in the U.S. and abroad; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Investor Relations Contact

Leigh Salvo

(415) 937-5402